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aoronary artery disease remains a major public
health problem in the U.S. as many Americans
experience an acute myocardial infarction (MI)
nd/or undergo percutaneous coronary intervention
PCI) each year. Given the attendant risks of mortality
nd morbidity, acute MI remains a principal focus of
ardiovascular therapeutics. Moreover, 30-day mortality
nd rehospitalization rates for acute MI are publicly
eported in an effort to promote optimal acute MI care,
nd aspects of MI care delivery are the focus of local,
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edical Center, Chicago, Illinois; #Denver Health Medical Center, Denver, Colo-
ado; **Harbor-UCLA Medical Center, Torrance, California; ††National Cardiovas-
ular Data Registry, Washington, DC; ‡‡Northern California Kaiser Permanente,
an Francisco, California; and the §§Denver Veterans Affairs Medical Center,
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merican College of Cardiology and the American Heart Association that receives
unding from the Merck/Schering-Plough Corporation and Bristol-Myers Squibb/
anofi Pharmaceutical Partnership. The CathPCI registry does not receive external
unding. For complete author disclosures, please see the end of this paper.c
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ccepted May 18, 2010.egional, and national quality initiatives (1–3). PCI
emains a central therapy for patients with symptomatic
oronary artery disease, particularly among patients with
cute MI, and has garnered tremendous attention in the
ast decade with issues such as the risks and benefits of
rug-eluting stents (DES) and adjunctive antithrombotic
herapies.
However, there are few representative data describing
ontemporary patterns of care and outcomes trends for
atients with acute MI and/or those undergoing PCI. This
s of particular importance because the process of updating
linical practice guidelines and quality metrics for acute MI
nd PCI has accelerated (4). Updates or revisions to the
merican College of Cardiology (ACC)/American Heart
ssociation (AHA) practice guidelines for PCI, ST-
egment elevation myocardial infarction (STEMI), and
nstable angina (UA)/non–ST-segment elevation myocar-
ial infarction (NSTEMI) have been published within the
ast 3 years, building upon prior versions published earlier in
he decade (5–7). The ACC and AHA have also published
erformance measures to direct quality assessment and
mprovement activities (8). However, data are lacking on
urrent guideline adherence as well as on trends in the
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July 20, 2010:254–63 Clinical Practice and Trends in AMI and/or PCIuality of care and outcomes for the large population of
atients in the U.S. with symptomatic coronary artery
isease.
Large-scale, national clinical registries provide an impor-
ant opportunity to evaluate current clinical practice. The
merican College of Cardiology’s National Cardiovascular
ata Registry (NCDR) comprises a suite of programs
nvolving 2,400 hospitals in the U.S. (www.ncdr.com).
e analyzed the NCDR Acute Coronary Treatment and
ntervention Outcomes Network (ACTION) Registry–Get
ith The Guidelines (AR-G) and Catheterization PCI
CathPCI) databases to characterize recent trends in treat-
ent and outcomes among patients with acute MI and
hose undergoing PCI. More specifically, we sought to
valuate patient and hospital characteristics, rates of guide-
ine adherence, procedural details, and in-hospital outcomes
elated to acute MI and PCI care over the last several years.
ethods
atient populations. The NCDR AR-G registry is a
ational, voluntary quality improvement registry program
hat is a partnership of the ACC and AHA and includes
ata on the in-hospital treatment of patients with acute MI,
oth STEMI and NSTEMI (9). The cohort analyzed for
R-G for this study includes all 131,980 STEMI and
STEMI patients enrolled from approximately 250 partic-
pating centers from the inception of AR-G in January 2007
hrough June 2009.
The NCDR CathPCI registry is a national quality
mprovement program focused on diagnostic cardiac cath-
terization and PCI, and is a partnership between the ACC
nd the Society for Cardiovascular Angiography and Inter-
entions. The CathPCI registry includes in-hospital data on
atients undergoing cardiac catheterization and PCI proce-
ures (10). The analytic cohort from CathPCI for this study
ncludes all 1,708,247 patients who underwent PCI in
anuary 2005 through June 2009; there were 436 participat-
ng hospitals in quarters 1 and 2, 2005, and 959 hospitals in
uarters 1 and 2, 2009.
tatistical methods. Comparisons of patient characteris-
ics, treatments, procedural complications, and in-
ospital outcomes were performed between the first 6
onths and the last 6 months of the respective analysis
ime periods for the AR-G (quarters 1 to 2, 2007 vs.
uarters 1 to 2, 2009) and CathPCI (quarters 1 to 2, 2005
s. quarters 1 to 2, 2009) registries. In the AR-G registry
ohort, the temporal comparisons were stratified by type
f MI (STEMI or NSTEMI). In the CathPCI registry
ohort, the comparisons were stratified by acute coronary
yndrome (ACS [UA, NSTEMI, and STEMI]) and
on-ACS (elective PCI) patients. Median values with
nterquartile ranges (25th, 75th percentiles) were used to
escribe continuous variables, and percentages were re-
orted for categorical variables. Continuous and ordinal
ategorical variables were compared using the stratum- Cdjusted Wilcoxon rank-sum
est, and nominal categorical
ariables were compared using
he stratum-adjusted chi-square
est.
For the AR-G registry, com-
osite performance scores and
efect-free care scores were de-
ermined separately for STEMI
nd NSTEMI patients, as de-
ailed in the Online Appendix
8,11,12). The p values for the
emporal trends of composite
erformance scores and defect-
ree care scores were obtained us-
ng linear regression with time as
n ordinal independent variable.
Temporal changes in clinical
utcomes (adjusted in-hospital
ortality and unadjusted major
leeding) were analyzed by
uarter separately for STEMI
nd NSTEMI patients for the
.5-year analysis time period
or the AR-G registry cohort.
he AR-G in-hospital mortal-
ty model was utilized to calcu-
ate adjusted mortality rates for the NSTEMI and
TEMI populations (13). For the CathPCI registry,
emporal changes in adjusted in-hospital mortality and
nadjusted periprocedural vascular and bleeding compli-
ations were analyzed by quarter separately in the ACS
nd non-ACS populations for the 4.5-year analysis time
eriod. The CathPCI risk-adjusted in-hospital mortality
odel was utilized to calculate adjusted in-hospital
ortality rates for the ACS and non-ACS populations
14). The p values for the temporal trends of in-hospital
utcomes and complications were obtained by modeling
ime as an ordinal independent variable using the logistic
eneralized estimating equations method with an ex-
hangeable working correlation matrix to account for
ithin-hospital clustering because patients at the same
ospital are more likely to have similar responses relative
o patients at other hospitals (i.e., within-center correla-
ion for responses) (15).
A p value of0.05 was considered statistically significant
or all tests. All analyses were performed using SAS software
version 9.2, SAS Institute, Cary, North Carolina).
esults
atient characteristics. Among the AR-G registry cohort,
here was an increase in the proportion of patients with
ardiac risk factors of current smoking, hypertension, and
yperlipidemia (Table 1). Among ACS patients in the
Abbreviations
and Acronyms
ACC  American College of
Cardiology
ACS  acute coronary
syndromes
ACTION  Acute Coronary
Treatment and Intervention
Outcomes Network
AHA  American Heart
Association
AR-G  ACTION Registry–Get
With The Guidelines
CathPCI  catheterization
and percutaneous coronary
intervention
DES  drug-eluting stent
LMWH  low-molecular-
weight heparin
NCDR  National
Cardiovascular Data Registry
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous coronary
intervention
UA  unstable anginaathPCI registry cohort, there was an increase in the
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Clinical Practice and Trends in AMI and/or PCI July 20, 2010:254–63roportion of patients with cardiac risk factors and signs of
eart failure on presentation and a decrease in the
roportion of patients with a history of prior MI, prior
CI, or prior coronary artery bypass graft surgery (Table 2).
urthermore, the proportion of ACS patients in the
athPCI registry cohort with UA decreased, whereas the
roportions of patients with NSTEMI and STEMI in-
reased (Table 2).
reatment and procedural details. In the AR-G registry,
ncreases in the use of anticoagulants were demonstrated in
oth STEMI and NSTEMI patients, whereas there were
ecreases in the use of acute beta-blockers and glycoprotein
Ib/IIIa inhibitors (Table 3). Among NSTEMI patients,
ecreased rates of overdosing of unfractionated heparin,
ow-molecular-weight heparin (LMWH), and glycoprotein
Ib/IIIa inhibitors were observed. Among STEMI patients,
he overall proportion of eligible patients who received
eperfusion therapy increased, paralleling an increase in the
roportion of reperfused patients who underwent primary
CI as well as an increase in the proportion of patients who
et quality benchmarks for rapid reperfusion times.
The use of early cardiac catheterization within 48 h and
he use of revascularization procedures increased in
STEMI patients. Increases in the use of discharge statins
nd clopidogrel, as well as cardiac rehabilitation referral,
ere observed for both STEMI and NSTEMI patients
able 1 Changes in Acute MI Patient Characteristics From the AR
Variables
STEMI
Q1–Q2 2007
(n  9,390)
Q1–Q2 200
(n  11,12
emographics
Age, yrs* 61 (52, 72) 60 (52, 71
Female sex, % 30.3 29.7
Race/ethnicity, %
White 84.8 84.8
African-American 7.3 7.9
Hispanic 3.4 3.6
Asian 1.5 1.8
Other 2.6 0.7
ardiac risk factors, %
Current smoking 40.8 43.7
Hypertension 60.2 62.5
Hyperlipidemia 46.7 52.2
Diabetes mellitus 23.0 22.7
edical history, %
Prior MI 19.0 18.8
Prior HF 5.7 5.4
Prior PCI 18.3 18.9
Prior CABG 7.5 7.0
Prior stroke 5.7 4.7
Prior PAD 6.0 5.5
resentation features
Symptom onset to presentation, h*‡ 1.7 (1.0, 3.7) 1.5 (0.9, 3.
Signs of HF, % 12.8 10.1
eGFR, cc/min*§ 72 (57, 87) 73 (58, 89
Continuous variables displayed as median values with 25th, 75th percentiles. †The p values compare
3% of NSTEMI patients and 12% of STEMI patients. §eGFR determined with Modification of Diet in R
AR-G Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry–Get W
ate; HF heart failure; MImyocardial infarction; NSTEMI non–ST-segment elevation myocard
TEMI  ST-segment elevation myocardial infarction.Table 3). UIn the CathPCI registry cohort, patterns of antithrom-
otic agent (anticoagulant and antiplatelet medications) use
ignificantly changed among both ACS and non-ACS
atients, with increasing use of bivalirudin and decreasing
se of unfractionated heparin, glycoprotein IIb/IIIa inhib-
tors, and LMWH (Table 4). The complexity of PCI
rocedures appeared to increase, with a larger proportion of
atients with type C lesions treated during PCI in both the
CS and non-ACS cohorts at the end of the analysis time
eriod. Significant decreases in the use of DES were
emonstrated in both ACS and non-ACS patients, but
ncreases in the use of new DES types (everolimus and
otarolimus) were also observed.
omposite measures. The acute MI composite perfor-
ance scores in the AR-G registry were high, but increased
rom 90% to 94% among STEMI patients and from 90% to
2% among NSTEMI patients (Fig. 1A). The defect-free
omposite care scores were lower, but significant improve-
ents in these scores were demonstrated in both STEMI
50% to 69%) and NSTEMI patients (58% to 66%)
Fig. 1B).
n-hospital/procedural outcomes. Among patients in
he AR-G registry, risk-adjusted in-hospital mortality
ates decreased from 6.2% to 5.5% among STEMI
atients and decreased from 4.3% to 3.9% among
STEMI patients during the study period (Fig. 2A).
gistry
NSTEMI
p Value
Q1–Q2 2007
(n  15,417)
Q1–Q2 2009
(n  16,247) p Value
0.24 67 (56, 79) 67 (56, 79) 0.69
0.19 39.3 37.9 0.30
0.006† 0.87†
84.1 83.2
8.7 9.9
3.4 3.6
1.5 1.5
1.8 0.7
0.02 28.8 29.8 0.09
0.19 72.1 76.7 0.0001
0.002 55.5 63.1 0.0001
0.70 33.7 35.0 0.27
0.29 27.0 27.9 0.60
0.86 16.0 16.9 0.12
0.84 22.3 24.2 0.01
0.39 18.0 18.7 0.38
0.04 9.6 9.7 0.89
0.56 11.3 12.3 0.01
0.0001 2.8 (1.3, 7.0) 2.4 (1.2, 6.1) 0.0001
0.0002 22.0 20.6 0.003
0.07 66 (48, 82) 68 (50, 86) 0.0001
tribution of race/ethnicity categories. ‡Data missing for time from symptom onset to presentation in
sease (MDRD) formula; dialysis patients excluded from calculations.
Guidelines; CABG coronary artery bypass graft surgery; eGFR estimated glomerular filtration
rction; PAD peripheral arterial disease; PCI percutaneous coronary intervention; Q quarter;-G Re
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atients and between 10.2% and 9.0% for NSTEMI
atients (Fig. 2B).
In the CathPCI registry, there were decreases in unad-
usted composite vascular complications (Fig. 3A) and
omposite bleeding complications (Fig. 3B) among ACS
nd non-ACS patients. Risk-adjusted in-hospital mortality
id not change substantially among ACS patients (2.2% to
.0%) and non-ACS patients (0.5% to 0.5%) during the
tudy period (Fig. 3C).
iscussion
he goal of this report was to evaluate contemporary clinical
ractice, as well as recent trends in treatments and out-
omes, among acute MI and PCI patients. Analyzing data
rom 2 large-scale national registry programs of the NCDR,
he most notable findings were improvements in the provi-
ion and timeliness of reperfusion therapy for STEMI
atients and in the use of guideline-recommended medica-
ions for both STEMI and NSTEMI, and a decrease in
able 2 Changes in PCI Patient Characteristics From the CathPCI
Variables
ACS
Q1–Q2 2005
(n  92,534)
Q1–Q2 20
(n  144,
emographics
Age, yrs* 63 (54, 73) 63 (54, 7
Female sex, % 34.1 33.0
Race, %
White 87.2 80.9
African-American 5.6 7.4
Hispanic 2.3 3.8
Asian 1.1 1.6
Native American 0.3 0.4
Other 3.3 5.8
ardiac risk factors, %
Current smoking 30.7 30.8
Hypertension 72.9 76.5
Hyperlipidemia 70.6 73.4
Diabetes mellitus 30.2 32.0
edical history, %
Prior MI 26.9 23.0
Prior HF 9.8 9.5
Prior PCI 29.3 26.0
Prior CABG 18.2 15.9
Prior CVD 11.2 10.8
Prior PVD 11.0 10.4
resentation features
Type of ACS, %
Unstable angina 54.5 47.1
NSTEMI 24.2 27.7
STEMI 21.3 25.2
Symptom onset to presentation 6 h, %
Among NSTEMI 30.0 38.4
Among STEMI 69.7 78.2
Signs of HF, % 9.4 10.7
Cardiogenic shock, % 2.9 3.5
eGFR, cc/min*‡ 73 (58, 88) 74 (59, 7
Continuous variables displayed as median values with 25th, 75th percentiles. †The p values compare t
ormula.
ACS  acute coronary syndromes; CathPCI  Catheterization PCI; CVD  cerebrovascular diseaCI-related procedural and vascular complications despite pn increase in procedural complexity. The results are gen-
rally encouraging with regard to key processes in the care of
cute MI and PCI patients and the translation of evidence
nto practice, yet also highlight areas of need for quality
mprovement, opportunities to improve patient outcomes,
nd targets for additional research.
Some of the most encouraging findings of this study were
he significant increases in the timeliness of acute MI
atient presentation after symptom onset, in the proportion
f eligible STEMI patients receiving reperfusion therapy,
nd in the timeliness of reperfusion therapy for STEMI.
hese findings may, in part, reflect the impact of local,
egional, and/or national quality improvement initiatives
hat have gained an increasing foothold in the U.S. in recent
ears. Such initiatives have focused on patient education and
wareness of acute MI symptoms in the community, reduc-
ng door-to-balloon times for primary PCI and improving
ystems of care for acute MI patients (1–3).
Building upon improvements in treatment for acute MI
stry
Non-ACS
p Value
Q1–Q2 2005
(n  50,532)
Q1–Q2 2009
(n  79,892) p Value
0.0001 66 (57, 74) 67 (58, 75) 0.0001
0.0001 33.3 33.0 0.16
0.0001† 0.0001†
87.0 79.4
5.4 7.2
2.2 4.0
1.2 1.8
0.2 0.3
3.8 7.2
0.65 19.1 18.8 0.30
0.0001 78.3 83.5 0.0001
0.0001 76.7 81.0 0.0001
0.0001 34.0 37.0 0.0001
0.0001 28.3 23.5 0.0001
0.008 11.4 11.8 0.04
0.0001 34.5 30.3 0.0001
0.0001 20.4 18.9 0.0001
0.001 11.8 12.2 0.06
0.0001 13.2 13.6 0.06
0.0001
N/A N/A
N/A N/A
N/A N/A
0.0001 N/A N/A
0.0001 N/A N/A
0.0001 8.2 10.0 0.0001
0.0001 0.5 0.7 0.0001
0.0001 72 (58, 87) 73 (58, 88) 0.0001
ibution of race categories. ‡The eGFR is determined with Modification of Diet in Renal Disease (MDRD)
A  not applicable; PVD  peripheral vascular disease; other abbreviations as in Table 1.Regi
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easure-recommended medication adherence over a rela-
ively short period of time at the end of the last decade, with
ery high rates of utilization of aspirin, clopidogrel, statins,
eta-blockers, angiotensin-converting enzyme inhibitors, or
ngiotensin-receptor blockers, as well as increased rates of
moking cessation counseling and referral for cardiac reha-
ilitation among eligible patients (5–8,16). Furthermore,
ignificant reductions in the rate of overdosing of anti-
hrombotic agents were demonstrated among NSTEMI
atients—a finding that highlights a new area of focus in the
cute MI performance measures (8,17). The improvements
n care demonstrated among NCDR-participating hospitals
ighlight the potential benefit of voluntary participation in
able 3 Changes in Treatments and Procedure Use in Acute MI Pa
STEMI
Q1–Q2 2007
(n  9,390)
Q1–Q2 20
(n  11,1
cute medications, %*
Aspirin 24 h 98.0 98.3
Clopidogrel 24 h 83.5 87.1
GP IIb/IIIa inhibitors 24 h 72.4 68.1
Any anticoagulant during hospitalization 93.6 95.6
Unfractionated heparin 78.2 81.0
LMWH 17.1 15.3
Bivalirudin 10.1 19.6
Beta-blockers 24 h 95.3 93.5
edication overdosing, %†
Unfractionated heparin N/A N/A
LMWH N/A N/A
GP IIb/IIIa inhibitors 9.5 9.8
eperfusion therapies, %
Overall reperfusion use‡ 90.8 93.8
Primary PCI 75.3 83.0
Fibrinolytics 17.3 12.5
Contraindication to reperfusion 17.0 13.1
Reperfusion timing‡
Direct arrival D2B 90 min 64.5 88.0
Transfer in D2B 90 min 7.6 18.7
Door to needle 30 min 50.5 65.6
ardiac procedures, %
Catheterization 85.4 93.0
Catheterization 48 h 82.4 90.9
PCI 75.9 81.5
CABG 7.1 7.0
ischarge medications, %*
Aspirin 98.5 98.4
Clopidogrel 90.4 91.9
Statin 90.6 94.5
Beta-blocker 97.0 97.3
ACEI or ARB 77.5 77.9
ischarge interventions, %
Smoking cessation counseling§ 96.6 97.3
Cardiac rehabilitation 76.7 83.5
Medication use determined only among patients without a recorded contraindication to each medica
ere discharged on comfort measures or to a hospice setting, and those discharged against medical a
GP) IIb/IIIa inhibitors: if full dose of tirofiban or eptifibatide given for STEMI or NSTEMI patients on dia
eparin (UFH): if either the initial bolus is 70 U/kg or the initial infusion is 15 U/kg/h (only for NSTE
ose given in the first 24 h is 10 mg over the 1 mg/kg dosing recommendation when creatinine clear
or NSTEMI patients). ‡Reperfusion therapy use determined only among patients without a recorded co
isplayed only for non–transfer-in patients without a documented reperfusion contraindication who rece
n Q1 to Q2, 2009). §Smoking cessation counseling determined only for current/recent smokers.
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin-receptor blocker; D2B  dlinical registries as regular data feedback and focused site cerformance improvement activities have been shown to
esult in greater improvements in guidelines adherence
ompared with pay-for-performance incentive programs
18). The AR-G registry participants, for example, receive
uarterly feedback reports that profile and benchmark com-
osite performance scores and defect-free care scores, med-
cation overdosing, and other metrics of guidelines adher-
nce for acute MI patients, whereas CathPCI participants
eceive quarterly reports focused upon procedural medica-
ions, details, and complications. However, the results from
his report also reinforce the need for ongoing quality
mprovement efforts as there are still gaps in the provision of
uideline-recommended medications among eligible acute
I patients, and further reductions in procedural compli-
s From the AR-G Registry
NSTEMI
p Value
Q1–Q2 2007
(n  15,417)
Q1–Q2 2009
(n  16,247) p Value
0.04 96.6 96.6 0.14
0.0001 57.8 56.6 0.15
0.0001 44.2 37.3 0.0001
0.0001 90.6 92.0 0.02
0.32 55.1 60.1 0.0001
0.01 42.2 40.3 0.0001
0.0001 10.1 15.6 0.0001
0.0003 92.9 89.2 0.0001
27.2 21.0 0.0001
18.0 15.1 0.003
0.50 10.7 8.8 0.004
0.0005 N/A N/A
0.0001 N/A N/A
0.0001 N/A N/A
0.0001 N/A N/A
0.0001 N/A N/A
0.0001 N/A N/A
0.48 N/A N/A
0.0001 71.6 76.2 0.0001
0.0001 59.3 62.5 0.0001
0.003 41.4 43.6 0.09
0.13 10.2 11.5 0.09
0.18 96.7 96.8 0.40
0.0002 72.8 74.2 0.0006
0.0001 84.7 88.3 0.0001
0.13 95.3 95.1 0.38
0.99 70.9 69.7 0.06
0.11 94.3 96.7 0.0001
0.0001 68.2 74.5 0.0001
s. For discharge medications, patients transferred out to another hospital, those who died, those who
ere excluded from the calculations. †Medication overdosing was determined as follows: glycoprotein
those with creatinine clearance 30 cc/min (tirofiban) or 50 cc/min (eptifibatide); unfractionated
ents); low-molecular-weight heparin (LMWH)–enoxaparin: if the initial dose is 1.05 mg/kg or if total
30 cc/min or over the 2 mg/kg dosing recommendation when creatinine clearance 30 cc/min (only
ication to reperfusion therapy or a non–systems reason for delay in reperfusion. Door-to-needle times
inolytic therapy at the hospital participating in AR-G (286 patients in Q1 to Q2, 2007, and 147 patients
alloon; other abbreviations as in Table 1.tient
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July 20, 2010:254–63 Clinical Practice and Trends in AMI and/or PCIWhile providing a benchmark for the future evaluation of
are processes and outcomes associated with acute MI and
CI procedures, the results from this report highlight
everal unique temporal changes in care among patients
ndergoing PCI. First, periprocedural antithrombotic treat-
ent strategies during PCI have significantly changed over
he last several years, with decreased use of glycoprotein
Ib/IIIa inhibitors and increased use of bivalirudin. This
airly rapid shift in clinical practice is concordant with the
ost recent guideline updates for management of acute MI
able 4 Changes in Treatments, Procedural Details, and In-Hospita
Variables
ACS
Q1–Q2 2005
(n  92,534)
Q1–Q2 20
(n  144,9
rocedural medications, %
GP IIb/IIIa inhibitors 57.3 44.5
Unfractionated heparin 63.9 58.7
LMWH 23.1 19.1
Bivalirudin 27.1 43.4
esion information, %*
Previously treated lesion 7.5 7.3
Bypass graft lesion 7.7 6.4
High-risk type C lesion 43.3 46.9
Lesion length 25 mm 20.4 21.3
Bifurcation lesion 11.4 12.3
rocedural details, %
Radial artery access 1.2 2.0
Multivessel PCI 13.9 12.9
Stents used during PCI†
DES 83.6 65.5
BMS 9.6 27.3
Angioplasty only 6.8 7.2
Type of DES used‡
Paclitaxel 57.3 21.2
Sirolimus 42.7 13.7
Everolimus N/A 54.8
Zotarolimus N/A 10.3
rocedural complications and results, %§
No reflow phenomenon 1.4 1.3
Dissection 2.4 2.1
Acute closure 0.7 0.7
Perforation 0.3 0.3
Procedural success 93.0 94.3
ascular complications, %
Access site occlusion 0.07 0.03
Peripheral embolization 0.08 0.04
Access vessel dissection 0.20 0.17
Pseudoaneurysm 0.42 0.46
Arteriovenous fistula 0.07 0.05
leeding complications, %
Access site bleeding 1.20 0.78
Retroperitoneal bleeding 0.33 0.42
Gastrointestinal bleeding 0.54 0.67
Genitourinary bleeding 0.20 0.13
Other bleeding location 0.60 0.97
n-hospital outcomes, %
Transfusion after PCI 5.1 4.7
Stroke 0.3 0.3
Emergency bypass surgery 0.4 0.4
Details for highest-risk lesion treated during the index PCI procedure. †If any drug-eluting stent (DES) us
atients who received a DES. §Procedural complications determined for the highest-risk lesion treated
BMS  bare-metal stent(s); other abbreviations as in Tables 1, 2, and 3.nd patients undergoing PCI, which reflect new data from wlinical trials evaluating anticoagulation strategies aimed at
educing bleeding (5–7,19,20). Second, while we verified
esults from other publications by demonstrating declining
ates of DES utilization in patients undergoing PCI for
oth ACS and non-ACS from 2005 to 2009, we have
hown the unique finding of recent widespread incorpora-
ion of new DES technologies among patients receiving a
ES in the CathPCI registry (21). Finally, the complexity
f PCI procedures appears to have increased with time, but
emporal reductions in vascular and bleeding complications
comes in PCI Patients From the CathPCI registry
Non-ACS
p Value
Q1–Q2 2005
(n  50,532)
Q1–Q2 2009
(n  79,892) p Value
0.0001 38.5 21.5 0.0001
0.0001 49.9 38.2 0.0001
0.0001 7.5 7.1 0.01
0.0001 37.8 57.3 0.0001
0.04 8.2 7.5 0.0001
0.0001 6.9 5.9 0.0001
0.0001 33.7 38.7 0.0001
0.0001 17.9 18.5 0.003
0.0001 11.2 12.1 0.0001
0.0001 1.6 2.3 0.0001
0.0001 15.5 15.3 0.18
0.0001 0.0001
85.7 73.0
7.6 20.4
6.7 6.6
0.0001 58.0 20.9 0.0001
42.0 13.7
N/A 54.8
N/A 10.6
0.04 0.5 0.6 0.39
0.0001 2.2 2.0 0.004
0.19 0.5 0.5 0.88
0.32 0.3 0.3 0.38
0.0001 94.0 94.8 0.01
0.0001 0.03 0.02 0.22
0.0002 0.02 0.02 0.89
0.04 0.24 0.19 0.07
0.11 0.38 0.38 0.84
0.11 0.08 0.05 0.02
0.0001 0.67 0.49 0.0001
0.0001 0.25 0.17 0.002
0.0001 0.27 0.15 0.0001
0.0001 0.07 0.05 0.10
0.0001 0.27 0.27 0.88
0.0001 2.6 2.3 0.0005
0.33 0.1 0.1 0.20
0.45 0.2 0.2 0.15
g PCI, then classified as DES; p value compares the distribution of stent types used during PCI. ‡Among
edural success defined as successful dilation of all lesions treated during the index PCI procedure.l Out
09
89)
ed durinere also demonstrated, so additional studies are needed to
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ave influenced the results and safety of PCI.
Mortality risk-adjustment models recently have been
erived and validated for both the AR-G and CathPCI
igure 1 Quarterly Changes in Composite Quality Scores Among P
A) Performance measure composite scores for ST-segment elevation myocard
ardial infarction (NSTEMI [trend p value  0.0002]). (B) Defect-free composit
trend p value  0.0008). Details regarding composite score calculations are
cute Coronary Treatment and Intervention Outcomes Network (ACTION) Regis
igure 2 Quarterly Changes in Risk-Adjusted In-Hospital Mortality
n the AR-G Registry From 2007 to 2009
A) Risk-adjusted in-hospital mortality for STEMI (trend p value  0.026) and N
TEMI (trend p value  0.81) and NSTEMI (trend p value  0.25). Major bleed
emoglobin values of 4 g/dl, intracranial hemorrhage, retroperitoneal hemor
leeding event and red blood cell transfusion (if baseline hemoglobin 9 g/dl
ajor bleeding calculations starting at the time of coronary artery bypass graft
ajor bleeding calculations). Blue lines  STEMI; red lines  NSTEMI. AMI egistries based on contemporary patient and procedural
ata reported in this paper, are currently being used to
eport risk-adjusted mortality in quarterly site feedback
eports for hospitals participating in the AR-G and/or
athPCI registries, and will be published separately (13,14).
ts With Acute MI in the AR-G Registry From 2007 to 2009
arction (STEMI [trend p value 0.0001]) and non–ST-segment elevation myo-
ormance measure scores for STEMI (trend p value  0.0001) and NSTEMI
ed in the Online Appendix. Blue lines  STEMI; red lines  NSTEMI. AR-G 
t With The Guidelines; MI  myocardial infarction.
nadjusted Major Bleeding Among Patients With Acute MI
I (trend p value  0.025). (B) Unadjusted in-hospital major bleeding for
efined as including any of the following: absolute drop from baseline to nadir
red blood cell transfusion (if baseline hemoglobin 9 g/dl), or witnessed
atients undergoing coronary artery bypass grafting were censored from the
e., pre-coronary artery bypass grafting bleeding events were captured in the
myocardial infarction; other abbreviations as in Figure 1.atien
ial inf
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try–Geand U
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rhage,
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ioned to evaluate temporal trends in risk-adjusted mortality
mong acute MI and PCI patients in this new decade and
ill complement prior analyses that demonstrated sustained
eductions in risk-adjusted mortality among acute MI pa-
ient across prior decades (22). Additionally, site-specific
eedback on adjusted mortality in the AR-G and CathPCI
egistries will complement current risk-adjusted mortality
eedback from claims data for hospitals seeking to optimize
heir care of acute MI and PCI patients. Finally, the NCDR
isk-adjustment models will inform and facilitate compara-
ive effectiveness research efforts such as the recently
warded Grand Opportunities grant, which will fund the
ombined ACC and Society of Thoracic Surgeons effort
esigned to evaluate the impact of percutaneous versus
urgical revascularization procedure.
The results of this report should be interpreted in the
ontext of several considerations. First, the data presented
ere intended to provide a fairly general representation of
urrent practice and recent trends; as such, these data are
igure 3 Quarterly Changes in Unadjusted Vascular Complications
isk-Adjusted In-Hospital Mortality Stratified by ACS and Non-ACS
A) Unadjusted composite vascular complications include all vascular complica
ACS) and 0.001 for non-ACS patients. (B) Unadjusted composite bleeding com
values  0.09 for ACS and 0.0001 for non-ACS patients. (C) Risk-adjuste
atients. Blue lines  ACS; red lines  non-ACS. CathPCI  Catheterization pargely descriptive without adjustment for case mix, so Fonclusions based on observed associations should be made
ith caution. Second, participation in the AR-G and
athPCI registries is largely voluntary, so the results may
ot be generalizable to all U.S. hospitals because “high
erforming” centers may preferentially participate, and non-
CI hospitals are not represented in the CathPCI registry
nd are under-represented in the AR-G registry. However,
oth registries have broad geographic participation, and are
he largest clinical registries for acute MI and PCI in the
.S. Nonetheless, hospital participation varied in the Cath-
CI registry from 436 participating hospitals in quarters 1
nd 2, 2005, compared with 959 hospitals in quarters 1 and
, 2009, whereas a relatively stable group of 250 hospitals
articipated in the AR-G program during the analysis time
eriod. This finding may partly explain the significant
ifferences in patient characteristics such as race and prior
evascularization from the beginning to the end of the
nalysis period for the CathPCI registry. These differences
n patient characteristics may have influenced the treatment,
rocedural, and outcome results presented in this analysis.
djusted Procedural Complications, and
nts Undergoing PCI in the CathPCI Registry From 2005 to 2009
listed in Table 4. Trend p values  0.0007 for acute coronary syndrome
tions include all bleeding complications/locations listed in Table 4. Trend
spital mortality. Trend p values  0.60 for ACS and  0.94 for non-ACS
neous coronary intervention., Una
Patie
tions
plica
d in-ho
ercutainally, only in-hospital outcomes and treatments are pro-
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ot be assessed.
onclusions
he contemporary profile of care patterns for patients with
cute MI and those undergoing PCI indicates that patient
nd procedural characteristics have changed over a relatively
hort time, while significant improvements in the receipt
nd timeliness of reperfusion therapy for STEMI, in the
verdosing of antithrombotic therapies, in the safety and
esults of PCI procedures, and in composite measures of
cute MI care were also demonstrated. These results serve as
benchmark for the ongoing evolution of strategies de-
igned to promote evidence-based and safe care for acute
I and PCI, and also highlight the importance of accu-
ately profiling differences in patient and procedural char-
cteristics to provide comparable feedback on clinical out-
omes to hospitals across the U.S.
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or the calculation of acute MI performance measure composite scores
nd defect-free care composite scores, please see the online version of this
rticle.
hanges in Acute MI Treatment From 2007 to 2009
ncreased reperfusion therapy use for eligible STEMI patients, from 90.8% to 93.8%.
ncreased STEMI door-to-balloon times 90 min for primary PCI, from 64.5% to
88.0%.Abbreviations as in Tables 1 and 2.
C
S
Necreased overdosing of unfractionated heparin (27.2% to 21.0%), low-molecular-
weight heparin (18.0% to 15.1%), and glycoprotein IIb/IIIa inhibitors (10.7% to
8.8%) among NSTEMI patients.
mproved acute MI composite performance measure scores (89.9% to 94.4%) and
defect-free care composite performance measure scores (49.9% to 69.4%) among
STEMI patients.
mproved acute MI composite performance measure scores (89.6% to 92.3%) and
defect-free care composite performance measure scores (58.2% to 66.2%) among
NSTEMI patients.bbreviations as in Tables 1 and 2. Ahanges in PCI Treatments and Procedural Details From
005 to 2009
or ACS patients, decreased use of periprocedural glycoprotein IIb/IIIa inhibitors
(57.3% to 44.4%) and increased use of bivalirudin (27.1% to 43.4%).
or non-ACS patients, decreased use of periprocedural glycoprotein IIb/IIIa inhibitors
(38.5% to 21.5%) and increased use of bivalirudin (37.8% to 57.3%).
igher procedural complexity, with an increased proportion of ACS (43.3% to 46.9%)
and non-ACS patients (33.7% to 38.7%) with type C lesions treated during PCI.
ecreased use of drug-eluting stents in both ACS (83.6% to 66.5%) and non-ACS
patients (85.7% to 73%).
ecreased use of sirolimus and paclitaxel stents (100% to 34.9%) with introduction
new stent types (everolimus and zotarolimus) among patients receiving a drug-
eluting stent.hanges in Acute MI Outcomes From 2007 to 2009
ignificant decreases in risk-adjusted in-hospital mortality among STEMI patients
(6.2% to 5.5%) and NSTEMI patients (4.3% to 3.9%).
o change in unadjusted in-hospital major bleeding among STEMI (11.3% to 11.0%)
and NSTEMI (10.2% to 9.0%) patients.bbreviations as in Table 1.
